Protalix Biotherapeutics Inc (PLX) - Total Liabilities
Based on the latest financial reports, Protalix Biotherapeutics Inc (PLX) has total liabilities worth $34.12 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Protalix Biotherapeutics Inc (PLX) net asset momentum to track the company's year-over-year net asset growth rate.
Protalix Biotherapeutics Inc - Total Liabilities Trend (1996–2025)
This chart illustrates how Protalix Biotherapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Protalix Biotherapeutics Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Protalix Biotherapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Protalix Biotherapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Solocal Group SA
PA:LOCAL
|
France | €369.97 Million |
|
Gurit Holding AG
SW:GURN
|
Switzerland | CHF182.25 Million |
|
Parsan Makina Parcalari Sanayi AS
IS:PARSN
|
Turkey | TL8.05 Billion |
|
Sensorion SA
PA:ALSEN
|
France | €16.36 Million |
|
Mikro MSC Bhd
KLSE:0112
|
Malaysia | RM19.25 Million |
|
Formuepleje Limittellus
CO:FPILIM
|
Denmark | Dkr2.00K |
|
Texmaco Infrastructure & Holdings Limited
NSE:TEXINFRA
|
India | Rs-13.26 Billion |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €3.44 Million |
Liability Composition Analysis (1996–2025)
This chart breaks down Protalix Biotherapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Protalix Biotherapeutics Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.55 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Protalix Biotherapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Protalix Biotherapeutics Inc (1996–2025)
The table below shows the annual total liabilities of Protalix Biotherapeutics Inc from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $34.12 Million | +12.94% |
| 2024-12-31 | $30.21 Million | -40.62% |
| 2023-12-31 | $50.87 Million | -23.43% |
| 2022-12-31 | $66.43 Million | -16.65% |
| 2021-12-31 | $79.70 Million | -16.08% |
| 2020-12-31 | $94.97 Million | -17.93% |
| 2019-12-31 | $115.71 Million | +1.49% |
| 2018-12-31 | $114.01 Million | +10.15% |
| 2017-12-31 | $103.51 Million | +12.26% |
| 2016-12-31 | $92.20 Million | +6.74% |
| 2015-12-31 | $86.38 Million | -35.57% |
| 2014-12-31 | $134.07 Million | -4.43% |
| 2013-12-31 | $140.28 Million | +70.90% |
| 2012-12-31 | $82.08 Million | +5.40% |
| 2011-12-31 | $77.88 Million | +2.41% |
| 2010-12-31 | $76.05 Million | -8.14% |
| 2009-12-31 | $82.79 Million | +1180.75% |
| 2008-12-31 | $6.46 Million | +45.19% |
| 2007-12-31 | $4.45 Million | +64.64% |
| 2006-12-31 | $2.70 Million | +3607.66% |
| 2005-12-31 | $72.93K | +3.48% |
| 2004-12-31 | $70.47K | -10.59% |
| 2003-12-31 | $78.82K | -0.32% |
| 2002-12-31 | $79.07K | +2.33% |
| 2001-12-31 | $77.28K | -86.22% |
| 2000-12-31 | $560.61K | +22.04% |
| 1999-12-31 | $459.36K | -67.61% |
| 1998-12-31 | $1.42 Million | -81.01% |
| 1997-12-31 | $7.47 Million | +1.73% |
| 1996-12-31 | $7.34 Million | -- |
About Protalix Biotherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also d… Read more